Literature DB >> 3609074

Metabolism of 14C-busulfan in isolated perfused rat liver.

M Hassan, H Ehrsson.   

Abstract

1,4-14C Busulfan gave one main metabolite in the isolated perfused rat liver during 4 hr cyclic perfusion. The cumulative bile excretion contained about 38% of the total radioactivity. About 1% of unchanged 14C-busulfan was excreted in the bile. The metabolite was identified as gamma-glutamyl-beta-(S-tetrahydrothiophenium) alanyl-glycine (sulfonium ion of glutathione) by 252Cf-plasma desorption time-of-flight mass spectrometry. The formation of the metabolite was drastically decreased when the glutathione-S-transferase was inhibited, which indicates that the major reaction of busulfan with glutathione is enzymatic in nature. The sulfonium ion was more stable in the perfusate (t1/2 = 22.4 hr, 37 degrees C) than in the bile (t1/2 = 3.2 hr, 37 degrees C) at pH 7.4.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3609074     DOI: 10.1007/BF03189864

Source DB:  PubMed          Journal:  Eur J Drug Metab Pharmacokinet        ISSN: 0378-7966            Impact factor:   2.441


  11 in total

1.  The mode of action of alkylating agents. II. Studies of the metabolism of myleran. The reaction of myleran with some naturally occurring thiols in vitro.

Authors:  J J ROBERTS; G P WARWICK
Journal:  Biochem Pharmacol       Date:  1961-06       Impact factor: 5.858

2.  Degradation of busulfan in aqueous solution.

Authors:  M Hassan; H Ehrsson
Journal:  J Pharm Biomed Anal       Date:  1986       Impact factor: 3.935

3.  Potential bis-alkylating agents for cancer chemotherapy. Approaches to the synthesis of 2-sulfonyl-1,4-bis(methanesulfonoxy)butanes.

Authors:  J M Wilbur
Journal:  J Med Chem       Date:  1978-11       Impact factor: 7.446

4.  Combined thin layer chromatography/mass spectrometry: an application of 252Cf plasma desorption mass spectrometry for drug monitoring.

Authors:  H Danigel; L Schmidt; H Jungclas; K H Pflüger
Journal:  Biomed Mass Spectrom       Date:  1985-09

Review 5.  The regulation of hepatic glutathione.

Authors:  N Kaplowitz; T Y Aw; M Ookhtens
Journal:  Annu Rev Pharmacol Toxicol       Date:  1985       Impact factor: 13.820

6.  Gas chromatographic determination of busulfan in plasma with electron-capture detection.

Authors:  M Hassan; H Ehrsson
Journal:  J Chromatogr       Date:  1983-10-14

7.  Determination of busulfan in plasma by GC-MS with selected-ion monitoring.

Authors:  H Ehrsson; M Hassan
Journal:  J Pharm Sci       Date:  1983-10       Impact factor: 3.534

8.  Inhibition of purified rat liver glutathione S-transferase isozymes by diuretic drugs.

Authors:  J T Ahokas; F A Nicholls; P J Ravenscroft; B T Emmerson
Journal:  Biochem Pharmacol       Date:  1985-06-15       Impact factor: 5.858

9.  Glutathione S-transferases catalyzed conjugation of 1,4-disubstituted butanes with glutathione in vitro.

Authors:  D H Marchand; M M Abdel-Monem
Journal:  Biochem Biophys Res Commun       Date:  1985-04-16       Impact factor: 3.575

Review 10.  The role of glutathione in detoxication.

Authors:  B Ketterer; B Coles; D J Meyer
Journal:  Environ Health Perspect       Date:  1983-03       Impact factor: 9.031

View more
  18 in total

1.  The Myeloablative Drug Busulfan Converts Cysteine to Dehydroalanine and Lanthionine in Redoxins.

Authors:  Michele Scian; Miklos Guttman; Samantha D Bouldin; Caryn E Outten; William M Atkins
Journal:  Biochemistry       Date:  2016-08-11       Impact factor: 3.162

2.  Prediction of Intravenous Busulfan Clearance by Endogenous Plasma Biomarkers Using Global Pharmacometabolomics.

Authors:  Yvonne S Lin; Savannah J Kerr; Timothy Randolph; Laura M Shireman; Tauri Senn; Jeannine S McCune
Journal:  Metabolomics       Date:  2016-09-15       Impact factor: 4.290

3.  Pharmacokinetics of high-dose busulphan in relation to age and chronopharmacology.

Authors:  M Hassan; G Oberg; A N Bekassy; J Aschan; H Ehrsson; P Ljungman; G Lönnerholm; B Smedmyr; A Taube; I Wallin
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

4.  Pharmacogenetics of intravenous and oral busulfan in hematopoietic cell transplant recipients.

Authors:  Nissa Abbasi; Barbara Vadnais; Jennifer A Knutson; David K Blough; Edward J Kelly; Paul V O'Donnell; H Joachim Deeg; Matthew A Pawlikowski; Rodney J-Y Ho; Jeannine S McCune
Journal:  J Clin Pharmacol       Date:  2010-12-06       Impact factor: 3.126

5.  Overexpression of glutathione S-transferase A1-1 in ECV 304 cells protects against busulfan mediated G2-arrest and induces tissue factor expression.

Authors:  Christoph A Ritter; Bernhard Sperker; Markus Grube; Dana Dressel; Christiane Kunert-Keil; Heyo K Kroemer
Journal:  Br J Pharmacol       Date:  2002-12       Impact factor: 8.739

Review 6.  The role of busulfan in bone marrow transplantation.

Authors:  M Hassan
Journal:  Med Oncol       Date:  1999-09       Impact factor: 3.064

7.  Kinetics and metabolism of 2-chloro-2'-deoxyadenosine and 2-chloro-2'-arabino-fluoro-2'-deoxyadenosine in the isolated perfused rat liver.

Authors:  F Albertioni; M Hassan; J Silberring; J Liliemark
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1995 Jul-Sep       Impact factor: 2.441

8.  Pharmacokinetic and metabolic studies of high-dose busulphan in adults.

Authors:  M Hassan; G Oberg; H Ehrsson; M Ehrnebo; I Wallin; B Smedmyr; T Tötterman; S Eksborg; B Simonsson
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

9.  Formulation and stability of busulfan for intravenous administration in high-dose chemotherapy.

Authors:  H P Bhagwatwar; S Phadungpojna; D S Chow; B S Andersson
Journal:  Cancer Chemother Pharmacol       Date:  1996       Impact factor: 3.333

10.  Influence of prophylactic anticonvulsant therapy on high-dose busulphan kinetics.

Authors:  M Hassan; G Oberg; M Björkholm; I Wallin; M Lindgren
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.